Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study was designed to check the efficacy of a new oral medical drug treatment, namely
Cabergoline, for the treatment of Cushing Disease due to pituitary adenoma.
Background: Cabergoline is a Dopamine 2 receptor agonist. Corticotroph adenoma has shown to
have the D2 receptor in in vitro studies.